ABSTRACT
Objetivo: estudiar el perfil de efectividad y seguridad de abiraterona en la práctica clínica, en pacientes con cáncer de próstata metastásico hormonoresistente. Métodos: se diseñó un estudio descriptivo retrospectivo de los pacientes diagnosticados con cáncer de próstata metastásico que recibieron tratamiento con abiraterona durante los mese de febrero 2012 a abril 2013. Las variables estudiadas fueron sexo, edad, escala del Eastern Cooperative Oncology Group (ECOG), tratamiento previo con docetaxel, antígeno prostático especifico (PSA) y supervivencia libre de progresión. La información se obtuvo de las historias clínicas, el programa de prescripción Savac® y el programa de validación farmacéutica FarmisâOncofarm®. Resultados: los 24 pacientes incluidos contaban una mediana de edad de 70 años. El estado funcional fue ECOG<2 en el 58,3 por ciento y ECOG≥2 en el 41,7 por ciento de los pacientes. El PSA disminuyó un 50 por ciento o más de su valor basal en el 52 por ciento de los pacientes. En cuanto a la supervivencia libre de progresión la mediana fue de 166 días (5,5 meses). En los pacientes con un ECOG≤2 la mediana fue de 231 días (7,7 meses) mientras que para los pacientes con ECOGË2 fue de 106 días (3,5 meses). Abiraterona presentó pocas reacciones adversas por lo que resulta un fármaco seguro, a pesar de presentar algunas reacciones de suma importancia. Conclusiones: los resultados obtenidos en nuestra práctica clínica difieren con los obtenidos en los estudios pivotales. Se observan mayor supervivencia libre de progresión en los pacientes con un ECOG≤1 y en los que nunca habían recibido quimioterapia previa(AU)
Objectives: to study the efficacy and safety profile of abiraterone in clinical practice to treat patients with hormone-resistant metastatic prostate cancer. Methods: retrospective and descriptive study of patients who were diagnosed with metastatic prostate cancer and were treated with abiraterone since February 2012 to April 2013. The studied variables were gender, age, level of Eastern Cooperative Oncology Group (ECOG) scale, prior treatment with docetaxel, prostate specific antigen (PSA), progression-free survival (PFS). Data sources included medical records, the Savac® prescription and the Farmis-Oncofarm® pharmaceutical validation programs. Results: twenty-four patients were included, with average age of 70 years. The ECOG performance status was less than 2 in 58,3 percent of patients whereas 41,7 percent of the patients showed ECOG equal to 2 or higher. The PSA decreased by 50 percent or more its basal value in 52 percent of the patients. As regards to PFS, the median was 166 days (5,5 months) in progression-free survival. In patients with ECOG≤2, the median PFS was 231 days (7,7 months), whereas for patients with ECOGË2,it was 106 days (3,5 months). Abiraterone has fewer side effects, so it may be considered a safe drug, although some are significant. Conclusions: the results obtained in our clinical practice differ from the ones obtained in the pivotal trials . Increased progression-free survival was observed in patients with an ECOG≤1 or less, and in those who had never received prior chemotherapy(AU)
Subject(s)
Humans , Male , Prostatic Neoplasms/drug therapy , Abiraterone Acetate/therapeutic use , Spain , Epidemiology, Descriptive , Retrospective StudiesABSTRACT
Objetivo: Conhecer a taxa de contaminação de hemoculturas e os seus fatores determinantes. Métodos: Foram analisadas 564 amostras de hemoculturas requisitadas num serviço hospitalar de urgências e questionados 46 enfermeiras(os) durante um período de seis meses. Resultados: Produziram-se 92 contaminações de hemoculturas de um total de 564 requisições num período de seis meses, o que corresponde a uma taxa de contaminação de 16,31%. O fator determinante foi a utilização de técnica pouco estéril. Conclusão: A taxa de contaminação das hemoculturas está diretamente relacionada aos procedimentos utilizados pelos profissionais de enfermagem e a carga de trabalho está diretamente associada a erros na técnica estéril de coleta. .
Objective: Determining the contamination rate of blood cultures and its determining factors. Methods: During a period of six months, were analyzed 564 blood culture samples requested at hospital emergency wards and 46 nurses were inquired. Results: In a period of six months, among a total of 564 requests, 92 blood cultures were contaminated, which corresponds to a contamination rate of 16.31%. The determining factor was the use of low-level sterile technique. Conclusion: The contamination rate of blood cultures is directly related to the procedures used by the nursing staff, and the workload is directly related to errors in the sterile technique of collection. .